Pivotal Research's Timothy Ramey reiterated a Buy rating and $90 price target on Herbalife. After watching "Betting On Zero" during the weekend, the analyst said that the documentary featured no new information on Herbalife, instead coming across as a "sad reflection" on Bill Ackman and Pershing Square's effort to tear the company down. Ramey argues that Ackman has "consistently been wrong" on Herbalife, and the analyst sees "no real hope" of the stock going to $0, as per the famed investor's predictions. It is his view, Ramey says, that Herbalife "will thrive in the go-forward, post-FTC period."